Hepatotoxicity induced by alendronate therapy

Osteoporosis International

Volumn 18, Issue 6, 2007, Pages 829-831

  Yanik, B ^a,b   Turkay, C ^a   Atalar, H ^a  

^a FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

^b NONE   (Turkey)

Author keywords

Adverse effects; Alendronate; Osteoporosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALENDRONIC ACID; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LABORATORY TEST; LIVER TOXICITY; OSTEOPOROSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SIDE EFFECT;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; LIVER DISEASES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 34247642670     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0323-2     Document Type: Article

References (16)

1. Peter C, Rodan GA (1999) Preclinical safety profile of alendronate. Int J Clin Pract Suppl 101:3-8
2. Felsenberg D, Alenfeld F, Bock O, Hammermeister C, Gowan W (1998) Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial. Maturitas 31:35-44
3. Watts N, Freedholm D, Daifotis A (1999) Alendronate: from the laboratory to the patient: the clinical tolerability profile of alendronate. Int J Clin Pract 101:51-61
4. Eisman JA, Rizzoli R, Roman-Ivorra J, Lipschitz S, Verbruggen N, Gaines KA, Melton ME (2004) Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 20:699-705
5. Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, Yates J, de Papp AE, Palmisano J (2002) Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 77:1044-1052
6. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461-468
7. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 10:183-192
8. Ferrari AP Jr, Domingues SH (1998) Esophageal ulcer and alendronate. Sao Paulo Med J 116:1882-1884
9. Nase JB, Suzuki JB (2006) Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 137:1115-1119
10. Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K (2006) Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 12:48-53
11. Coleman CI, Perkerson KA, Lewis A (2004) Alendronate-induced auditory hallucinations and visual disturbances. Pharmacotherapy 24:799-802
12. Mayoral W, Lewis JH, Zimmerman H (1999) Drug-induced liver disease. Curr Opin Gastroenterol 15:208-216
13. Lieverse RJ (1998) Hepatitis after alendronate. Neth J Med 53:271-272
14. Halabe A, Lifschitz BM, Azuri J (2000) Liver damage due to alendronate. N Engl J Med 343:365-366
15. de La Serna Higuera C, Perez Villoria A, Rodriguez Gomez S, Martinez Moreno J, Betancourt Gonzalez A, Martin Arribas M (2001) Alendronate-induced hepatocellular lesion Gastroenterol Hepatol 24:244-246
16. Carrere C, Duval JL, Godard B, De Jaureguiberry JP, Ciribilli JM (2002) Severe acute hepatitis induced by alendronate. Gastroenterol Clin Biol 26:179-180